APR Applied Pharma Research S.A. and Eris Pharmaceuticals (Australia) Pty Ltd. Announce the Signature of a License Agreement for the Distribution and Marketing of the HALYKOO Line in Australia and New Zealand
2.12.2015 14:46 | Business Wire
APR Applied Pharma Research S.A. (“APR”), the independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products, and Eris Pharmaceuticals (Australia) Pty Ltd. (“Eris Pharma”), a leading pharmaceutical company, currently specialized in the development and marketing of healthcare products in Australia and the emerging markets, today announce the beginning of a partnership for the promotion, distribution and marketing of the Halykoo baby healthcare product line in Australia and New Zealand.
Thanks to this license agreement, APR records another success in widening its global network of partners for the brand Halykoo, which has been recently launched in Italy and will be rolled out in 2016 in several countries across the world, proving Halykoo high level of quality, innovation and appeal on an international basis.
This partnership will enable Eris Pharma to enter the pediatric market segment through the offer of the new and innovative brand, Halykoo - the first complete line of products including tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.
“We are proud to have the chance to launch the Halykoo range in Australia and New Zealand” – said Mr. Panos Athanasiou, CEO of Eris Pharma. “The HALYKOO brand will complement consistently the product portfolio of Eris Pharma, that currently covers a wide range of prescription medicine, OTC products, Medical Devices and skincare products, most of which are mainly addressed to adults. Adding the Halykoo products in our portfolio will enable us to bring to the Australian & New Zealand markets products targeting currently unaddressed needs of children from a very young age, providing the needed confidence and reassurance to their parents . ”
Eris Pharma Sales Director Mr. Karl Hansen asserted that “Halykoo represents a great opportunity to successfully compete in as valuable an area of the market as pediatric healthcare. Australian parents spend many billions of dollars each year ensuring the healthcare needs of their children are met, but are often confused in a congested marketplace. At the same time they are concerned about the ingredients in the products they buy, which is why the Halykoo range offers unique, innovative products that parents can trust. Eris Pharma is very excited to introduce Halykoo to Australian parents and is looking forward to playing a continuing role in their children’s health.”
Over the last 20 years, APR has developed high-quality products certified according to the strictest international regulations. “We are delighted to hail this partnership with Eris Pharma, which allows APR to enter new attractive overseas markets, Australia and New Zealand, and proves Halykoo internationally valuable positioning and potential” said Paolo Galfetti, CEO and co-founder of APR”. “We reckon that Eris Pharma is the right partner to introduce to caregivers and consumers an innovative and unique product option as Halykoo”.
Halykoo is a new global brand in the pediatric self-care market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies.
Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies.
Halykoo products are the perfect combination of responsible, Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural BIO certified components), to careful dosing of the active principles and full compliance with the strictest safety standards - and the right delivery system for the right age.
For more info about Halykoo, please visit: www.halykoo.com
About Eris Pharmaceuticals (Australia) Pty Ltd
Eris Pharmaceuticals (Eris Pharma) was established in Australia in 2009 as a generic pharmaceuticals company. Today, Eris Pharma is an international leader in developing and distributing premium quality healthcare products in the generics, dermocosmetics, OTC and medical device categories. Eris Pharma’s focus is on premium products in numerous therapeutic categories that contain only the highest quality ingredients in specialised formulations.
Eris Pharma distributes its products to over 25 markets worldwide and has an aggressive plan to grow the business, focusing heavily on the Australian market. Underlying this ambition is Eris Pharma’s desire to form strong relationships that deliver only the best possible outcomes for customers and end users.
For more info about Eris Pharmaceuticals, please visit www.eris-pharma.com.au.
About APR Applied Pharma Research s.a.
APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch.
Eris Pharmaceuticals (Australia) Pty Ltd
Panos Athanasiou; Chief Executive Officer
T.: +61 4 14143678 or email to email@example.com
Karl Hansen; Sales Director - Australia and New Zealand
T.: +61 4 17062642 or email to firstname.lastname@example.org
APR Applied Pharma Research s.a.
Paolo Galfetti; Chief Executive Officer
T: +41 91 6957020 or email to email@example.com
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies20.8.2017 23:30 | Pressemelding
Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170820005028/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) “Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” said Christopher Hansung Ko, President and CEO, Samsung Bioepis. “Five years ago, we entered
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom